NASDAQ
01.05.26 | 22:00
4,090 US-Dollar
+2,00 % +0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 21.04. | Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer | 2 | GlobeNewswire (USA) | ||
| 17.04. | Zentalis präsentiert Daten zu Krebsmedikament Azenosertib - Aktie unter Druck | 2 | Investing.com Deutsch | ||
| 17.04. | Zentalis presents preclinical data on cancer drug azenosertib | 10 | Investing.com | ||
| 17.04. | Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 17.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Jefferies raises Zentalis stock price target on ovarian cancer trial data | 5 | Investing.com | ||
| 10.04. | Guggenheim erhöht Kursziel für Zentalis-Aktie nach positiven Daten zu Krebsmedikament | 7 | Investing.com Deutsch | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.04. | Guggenheim raises Zentalis stock price target on ovarian cancer drug data | 1 | Investing.com | ||
| 10.04. | H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection | 1 | Investing.com | ||
| 09.04. | Zentalis legt 400-mg-Dosis für Studie zu Eierstockkrebs-Medikament fest | 10 | Investing.com Deutsch | ||
| 09.04. | Zentalis selects 400mg dose for ovarian cancer drug trial | 1 | Investing.com | ||
| 09.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 27.03. | TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating | 4 | Investing.com | ||
| 27.03. | H.C. Wainwright reiterates Zentalis stock rating, $10 target | 2 | Investing.com | ||
| 27.03. | Oppenheimer reiterates Zentalis stock rating on ovarian cancer drug | 2 | Investing.com | ||
| 27.03. | Zentalis: Oppenheimer bestätigt "Outperform"-Rating für Aktie dank Krebsmedikament | 2 | Investing.com Deutsch | ||
| 26.03. | Zentalis Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.03. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 39,200 | +0,22 % | Moderna, Inc Q1 Loss Climbs | WASHINGTON (dpa-AFX) - Moderna, Inc (MRNA) revealed Loss for its first quarter of -$1.343 billionThe company's earnings came in at -$1.343 billion, or -$3.40 per share. This compares with -$971... ► Artikel lesen | |
| VALNEVA | 2,307 | -0,30 % | Valneva-Aktie mit Kapitalspritze: Rebound-Chance oder weiterer Absturz? | Beim Impfstoffentwickler Valneva gibt es weiterhin wenig erfreuliche Nachrichten für Aktionäre. Nachdem der Kurs bereits massiv unter Druck geraten war, hat das Unternehmen nun eine Kapitalerhöhung... ► Artikel lesen | |
| NOVAVAX | 7,030 | +4,15 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,370 | +1,09 % | US-Expansion im Fokus: NurExone richtet den Blick auf den weltweit größten Biotechmarkt | ||
| IMMUNITYBIO | 6,130 | +1,32 % | IBRX: What Anktiva's Bladder Data Says About 2026 Sales | ||
| CARDIFF ONCOLOGY | 1,441 | -1,97 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALDEYRA | 1,310 | +0,77 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,860 | 0,00 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 | ||
| GUARDANT HEALTH | 69,55 | -6,27 % | Guardant Health und Nuvalent schließen Partnerschaft für Krebsdiagnostik | ||
| OCULAR THERAPEUTIX | 7,950 | -0,62 % | Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data | ||
| COHERUS ONCOLOGY | 1,516 | +0,20 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ESPERION | 1,688 | -0,68 % | Esperion Therapeutics, Inc.: Esperion to be Acquired by ARCHIMED | Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,200 | +0,82 % | Voyager Therapeutics, Inc.: Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease | ||
| MACROGENICS | 2,620 | 0,00 % | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen | |
| CORMEDIX | 6,422 | 0,00 % | CorMedix, Inc.: CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients | - The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 - - Study showed favorable benefit for toxicity related discontinuations... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,090 Euro und damit +2,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.